{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T10:58:49Z","timestamp":1777114729697,"version":"3.51.4"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CEN Case Rep"],"DOI":"10.1007\/s13730-025-01082-2","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T08:48:54Z","timestamp":1770281334000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Relapse of minimal change nephrotic syndrome after initiation of sulfamethoxazole\u2013trimethoprim combination therapy: a case report"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-7952-4175","authenticated-orcid":false,"given":"Takuya","family":"Sugiura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shun","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naohiro","family":"Sakaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshikazu","family":"Ozeki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Yokoe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaoru","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoichi","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"key":"1082_CR1","doi-asserted-by":"publisher","first-page":"761600","DOI":"10.3389\/fmed.2021.761600","volume":"8","author":"S Purohit","year":"2021","unstructured":"Purohit S, Piani F, Ordo\u00f1ez FA, de Lucas-Collantes C, Bauer C, Cara-Fuentes G. Molecular mechanisms of proteinuria in minimal change disease. Front Med (Lausanne). 2021;8:761600. https:\/\/doi.org\/10.3389\/fmed.2021.761600.","journal-title":"Front Med (Lausanne)"},{"issue":"7880","key":"1082_CR2","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/S0140-6736(74)91880-7","volume":"2","author":"RJ Shalhoub","year":"1974","unstructured":"Shalhoub RJ. Pathogenesis of lipoid nephrosis: a disorder of T-cell function. Lancet. 1974;2(7880):556\u201360.","journal-title":"Lancet"},{"key":"1082_CR3","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s00467-022-05739-3","volume":"38","author":"A Trautmann","year":"2023","unstructured":"Trautmann A, Boyer O, Hodson E, et al. IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome. Pediatr Nephrol. 2023;38:877\u2013919. https:\/\/doi.org\/10.1007\/s00467-022-05739-3.","journal-title":"Pediatr Nephrol"},{"key":"1082_CR4","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s13730-023-00822-9","volume":"13","author":"M Teragaki","year":"2024","unstructured":"Teragaki M, Tanaka M, Yamamoto H, Watanabe T, Takeoka J, Fukuumi A, et al. Relapse of minimal change disease following the third mRNA COVID-19 vaccination: a case report and literature review. CEN Case Rep. 2024;13:53\u20138. https:\/\/doi.org\/10.1007\/s13730-023-00822-9.","journal-title":"CEN Case Rep"},{"issue":"1","key":"1082_CR5","doi-asserted-by":"publisher","first-page":"e0297568","DOI":"10.1371\/journal.pone.0297568","volume":"19","author":"KS Kechagias","year":"2024","unstructured":"Kechagias KS, et al. Minimal change disease following COVID-19 vaccination: systematic review and meta-analysis. PLoS ONE. 2024;19(1):e0297568. https:\/\/doi.org\/10.1371\/journal.pone.0297568.","journal-title":"PLoS ONE"},{"issue":"2","key":"1082_CR6","doi-asserted-by":"publisher","first-page":"111","DOI":"10.20408\/jti.2018.048","volume":"32","author":"J Depa","year":"2019","unstructured":"Depa J, Coritsidis G. Recurrence of minimal change disease following a motor vehicle trauma: an atypical cause and review of literature. J Trauma Injury. 2019;32(2):111\u20134. https:\/\/doi.org\/10.20408\/jti.2018.048.","journal-title":"J Trauma Injury"},{"issue":"1","key":"1082_CR7","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1681\/ASN.2021060794","volume":"33","author":"AJB Watts","year":"2022","unstructured":"Watts AJB, Keller KH, Lerner G, Rosales I, Collins AB, Sekulic M, et al. Discovery of autoantibodies targeting nephrin in minimal change disease supports a novel autoimmune etiology. J Am Soc Nephrol. 2022;33(1):238\u201352.","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"1082_CR8","doi-asserted-by":"publisher","DOI":"10.1172\/JCI186769","volume":"135","author":"FE Hengel","year":"2025","unstructured":"Hengel FE, Dehde S, Kretz O, Engesser J, Zimmermann T, Huber TB, et al. Passive transfer of patient-derived anti-nephrin autoantibodies causes a podocytopathy with minimal change lesions. J Clin Invest. 2025;135(5):e186769. https:\/\/doi.org\/10.1172\/JCI186769.","journal-title":"J Clin Invest"},{"key":"1082_CR9","unstructured":"Drugs.com. Atorvastatin side effects [Internet]. Drugs.com; 2024 Dec 3 [cited 2025 Nov 7]. Available from: https:\/\/www.drugs.com\/sfx\/atorvastatin-side-effects.html"},{"issue":"10","key":"1082_CR10","first-page":"e43","volume":"11","author":"L Chularojanamontri","year":"2012","unstructured":"Chularojanamontri L, Jiamton S, Manapajon A, Suvanasuthi S, Kulthanan K, Dhana N, et al. Cutaneous reactions to proton pump inhibitors: a case-control study. J Drugs Dermatol. 2012;11(10):e43\u20137 (PMID: 23134998).","journal-title":"J Drugs Dermatol"},{"key":"1082_CR11","doi-asserted-by":"publisher","first-page":"e01917","DOI":"10.1016\/j.idcr.2023.e01917","volume":"34","author":"S Sircar","year":"2023","unstructured":"Sircar S, Rayan M, Okonoboh P. TMP-SMX induced type 4 hypersensitivity with multi-organ involvement. IDCases. 2023;34:e01917. https:\/\/doi.org\/10.1016\/j.idcr.2023.e01917.","journal-title":"IDCases"},{"key":"1082_CR12","doi-asserted-by":"publisher","first-page":"658593","DOI":"10.3389\/fimmu.2021.658593","volume":"12","author":"J Pratoomwun","year":"2021","unstructured":"Pratoomwun J, et al. Characterization of T cell responses to SMX and SMX NO in co trimoxazole hypersensitivity patients expressing HLA B*13:01. Front Immunol. 2021;12:658593. https:\/\/doi.org\/10.3389\/fimmu.2021.658593.","journal-title":"Front Immunol"},{"issue":"3","key":"1082_CR13","doi-asserted-by":"publisher","first-page":"421","DOI":"10.3265\/Nefrologia.pre2014.Mar.12388","volume":"34","author":"MA P\u00e9rez-Valdivia","year":"2014","unstructured":"P\u00e9rez-Valdivia MA, L\u00f3pez-Mendoza M, Toro-Prieto FJ, Cabello-Chaves V, Toro-Ramos M, Mart\u00edn-Herrera MC, et al. Relapse of minimal change disease nephrotic syndrome after administering intravitreal bevacizumab. Nefrolog\u00eda (Madr). 2014;34(3):421\u20132. https:\/\/doi.org\/10.3265\/Nefrologia.pre2014.Mar.12388.","journal-title":"Nefrolog\u00eda (Madr)"},{"key":"1082_CR14","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/ped.12017","volume":"55","author":"T Sato","year":"2013","unstructured":"Sato T, Kawasaki Y, Waragai T, et al. Relapse of minimal change nephrotic syndrome after intravitreal bevacizumab. Pediatr Int. 2013;55:46\u20138 (PMID: 23782377).","journal-title":"Pediatr Int"}],"container-title":["CEN Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-025-01082-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13730-025-01082-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-025-01082-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T08:48:57Z","timestamp":1770281337000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13730-025-01082-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":14,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["1082"],"URL":"https:\/\/doi.org\/10.1007\/s13730-025-01082-2","relation":{},"ISSN":["2192-4449"],"issn-type":[{"value":"2192-4449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,5]]},"assertion":[{"value":"18 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Shoichi Maruyama has received honoraria and research support from several pharmaceutical companies, as disclosed in the ICMJE COI form.All other authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"During the preparation of this work, the author(s) used ChatGPT (OpenAI) to assist in language editing and improving readability. After using this tool, the author(s) reviewed and edited the content as needed and take full responsibility for the content of the publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Informed consent was obtained from the patient.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"47"}}